Nautilus Biotechnology Q1 2024 GAAP EPS $(0.15) Beats $(0.17) Estimate
Portfolio Pulse from Benzinga Newsdesk
Nautilus Biotechnology reported Q1 2024 GAAP EPS of $(0.15), surpassing the $(0.17) estimate, marking an 11.76% beat but a 25% increase in losses from the previous year.
April 30, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nautilus Biotechnology reported a smaller-than-expected loss per share for Q1 2024, beating estimates but showing increased losses from the previous year.
Beating EPS estimates typically has a positive impact on investor sentiment and can lead to a short-term increase in stock price. However, the increased losses year-over-year might temper some of the positive momentum.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100